Korea Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s five largest COVID-19 vaccine manufacturing hubs by 2025. Here, we provide a rundown of some of the key companies involved…
Japan Writing in the October edition of DIA’s Global Forum magazine, Chief Executive of Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Yasuhiro Fujiwara outlines how his agency has begun to utilise real-world data (RWD) and real-world evidence (RWE) in its regulatory decision-making processes and how this will evolve moving forward. …
Denmark Copenhagen Capacity is Greater Copenhagen’s official organization for investment, promotion, and business development. Its CEO/managing director, Asbjørn Overgaard, outlines the fundamentals attracting life sciences firms to the region, stakeholders’ key investment concerns, and the work still to be done on closer alignment with neighbouring Sweden. Our goals are threefold:…
APAC Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand for the research, development, and manufacturing of therapies and vaccines against COVID-19. Van Parys also outlines the opportunities and challenges…
APAC Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and Prapassorn Thanaphollert of the World Health Organization highlight the progress towards regulatory harmonization in ASEAN and work between country-level regulatory…
Global The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and vaccine hesitancy and scepticism rife in certain countries. Here, three country managers from Pfizer – which is aiming to manufacture…
APAC The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures, infrastructures, and economic development. Managing a life sciences company across multiple countries in this region can be extremely challenging but hugely important on both a human…
Singapore Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the COVID-19 pandemic has sped up the industry’s digitalisation efforts, and how Asian innovation stands to develop in the coming years.…
Singapore Marco Lee, APAC head for medical device firm Avanos explains how the company’s products are catered to patient needs in the region and talks through key growth drivers, the impact of COVID-19, and the talent development strategy he has put in place. The COVID-19 pandemic has led to improved…
Singapore Cindy Engelbart, director of mid-sized logistics player Agility’s life science operations in APAC, highlights some of the key trends in global logistics that have emerged from the COVID-19 pandemic, how digital and data-driven solutions are being utilised in Asia, and the ways in which Agility differentiates itself in a crowded…
Singapore IQVIA Biotech JAPAC’s Dr Senthil Sockalingam outlines the evolving needs of the flood of early-stage drug discovery ventures in Asia, how biotechs in the region differ from their counterparts in the US and Europe, and the most important digitalisation trends to emerge from the COVID-19 pandemic. Almost 50 percent…
See our Cookie Privacy Policy Here